Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease

Ramachandiran Nandhagopal, Lisa Kuramoto, Michael Schulzer, Edwin Mak, Jacqueline Cragg, Jess McKenzie, Siobhan McCormick, Thomas J. Ruth, Vesna Sossi, Raul De La Fuente-Fernandez, A. Jon Stoessl

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Parkinson's disease is a relentlessly progressive neurodegenerative disease. Breakdown of compensatory mechanisms influencing putaminal dopamine processing could contribute to the progressive motor symptoms. We studied a cohort of 78 subjects (at baseline) with sporadic Parkinson's disease and 35 healthy controls with multi-tracer positron emission tomography scans to investigate the evolution of adaptive mechanisms influencing striatal dopamine processing in Parkinson's disease progression. Presynaptic dopaminergic integrity was assessed with three radioligands: (i) [11C](±) dihydrotetrabenazine, to estimate the density of vesicular monoamine transporter type 2; (ii) [11C]d-threo-methylphenidate, to label the dopamine transporter; and (iii) 6-[18F]fluoro-l-DOPA, to assess the activity of aromatic amino acid decarboxylase and storage of 6-[18F]- fluorodopamine in synaptic vesicles. The subjects with Parkinson's disease and the healthy controls underwent positron emission tomography scans at the initial visit and after 4 and 8 years of follow-up. Non-linear multivariate regression analyses with random effects were utilized to model the longitudinal changes in tracer values in the putamen standardized relative to normal controls. We found evidence for possible upregulation of dopamine synthesis and downregulation of dopamine transporter in the more severely affected putamen in the early stage of Parkinson's disease. The standardized 6-[18F]fluoro-l-DOPA and [11C]d-threo-methylphenidate values tended to approach [ 11C](±)dihydrotetrabenazine values in the putamen in later stages of disease (i.e. for [11C](±)dihydrotetrabenazine values

Original languageEnglish
Pages (from-to)3290-3298
Number of pages9
JournalBrain
Volume134
Issue number11
DOIs
Publication statusPublished - 2011

Fingerprint

Corpus Striatum
Parkinson Disease
Dopamine
Putamen
Dopamine Plasma Membrane Transport Proteins
Methylphenidate
Positron-Emission Tomography
Vesicular Monoamine Transport Proteins
Aromatic-L-Amino-Acid Decarboxylases
Synaptic Vesicles
Neurodegenerative Diseases
Disease Progression
Up-Regulation
Down-Regulation
Multivariate Analysis
Regression Analysis
dihydrotetrabenazine

Keywords

  • compensatory changes
  • motor dysfunction
  • Parkinson's disease
  • PET
  • striatal dopamine processing

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., McKenzie, J., ... Stoessl, A. J. (2011). Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain, 134(11), 3290-3298. https://doi.org/10.1093/brain/awr233

Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. / Nandhagopal, Ramachandiran; Kuramoto, Lisa; Schulzer, Michael; Mak, Edwin; Cragg, Jacqueline; McKenzie, Jess; McCormick, Siobhan; Ruth, Thomas J.; Sossi, Vesna; De La Fuente-Fernandez, Raul; Stoessl, A. Jon.

In: Brain, Vol. 134, No. 11, 2011, p. 3290-3298.

Research output: Contribution to journalArticle

Nandhagopal, R, Kuramoto, L, Schulzer, M, Mak, E, Cragg, J, McKenzie, J, McCormick, S, Ruth, TJ, Sossi, V, De La Fuente-Fernandez, R & Stoessl, AJ 2011, 'Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease', Brain, vol. 134, no. 11, pp. 3290-3298. https://doi.org/10.1093/brain/awr233
Nandhagopal, Ramachandiran ; Kuramoto, Lisa ; Schulzer, Michael ; Mak, Edwin ; Cragg, Jacqueline ; McKenzie, Jess ; McCormick, Siobhan ; Ruth, Thomas J. ; Sossi, Vesna ; De La Fuente-Fernandez, Raul ; Stoessl, A. Jon. / Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. In: Brain. 2011 ; Vol. 134, No. 11. pp. 3290-3298.
@article{9a1487c07d9849d3b6b713168e821f95,
title = "Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease",
abstract = "Parkinson's disease is a relentlessly progressive neurodegenerative disease. Breakdown of compensatory mechanisms influencing putaminal dopamine processing could contribute to the progressive motor symptoms. We studied a cohort of 78 subjects (at baseline) with sporadic Parkinson's disease and 35 healthy controls with multi-tracer positron emission tomography scans to investigate the evolution of adaptive mechanisms influencing striatal dopamine processing in Parkinson's disease progression. Presynaptic dopaminergic integrity was assessed with three radioligands: (i) [11C](±) dihydrotetrabenazine, to estimate the density of vesicular monoamine transporter type 2; (ii) [11C]d-threo-methylphenidate, to label the dopamine transporter; and (iii) 6-[18F]fluoro-l-DOPA, to assess the activity of aromatic amino acid decarboxylase and storage of 6-[18F]- fluorodopamine in synaptic vesicles. The subjects with Parkinson's disease and the healthy controls underwent positron emission tomography scans at the initial visit and after 4 and 8 years of follow-up. Non-linear multivariate regression analyses with random effects were utilized to model the longitudinal changes in tracer values in the putamen standardized relative to normal controls. We found evidence for possible upregulation of dopamine synthesis and downregulation of dopamine transporter in the more severely affected putamen in the early stage of Parkinson's disease. The standardized 6-[18F]fluoro-l-DOPA and [11C]d-threo-methylphenidate values tended to approach [ 11C](±)dihydrotetrabenazine values in the putamen in later stages of disease (i.e. for [11C](±)dihydrotetrabenazine values",
keywords = "compensatory changes, motor dysfunction, Parkinson's disease, PET, striatal dopamine processing",
author = "Ramachandiran Nandhagopal and Lisa Kuramoto and Michael Schulzer and Edwin Mak and Jacqueline Cragg and Jess McKenzie and Siobhan McCormick and Ruth, {Thomas J.} and Vesna Sossi and {De La Fuente-Fernandez}, Raul and Stoessl, {A. Jon}",
year = "2011",
doi = "10.1093/brain/awr233",
language = "English",
volume = "134",
pages = "3290--3298",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease

AU - Nandhagopal, Ramachandiran

AU - Kuramoto, Lisa

AU - Schulzer, Michael

AU - Mak, Edwin

AU - Cragg, Jacqueline

AU - McKenzie, Jess

AU - McCormick, Siobhan

AU - Ruth, Thomas J.

AU - Sossi, Vesna

AU - De La Fuente-Fernandez, Raul

AU - Stoessl, A. Jon

PY - 2011

Y1 - 2011

N2 - Parkinson's disease is a relentlessly progressive neurodegenerative disease. Breakdown of compensatory mechanisms influencing putaminal dopamine processing could contribute to the progressive motor symptoms. We studied a cohort of 78 subjects (at baseline) with sporadic Parkinson's disease and 35 healthy controls with multi-tracer positron emission tomography scans to investigate the evolution of adaptive mechanisms influencing striatal dopamine processing in Parkinson's disease progression. Presynaptic dopaminergic integrity was assessed with three radioligands: (i) [11C](±) dihydrotetrabenazine, to estimate the density of vesicular monoamine transporter type 2; (ii) [11C]d-threo-methylphenidate, to label the dopamine transporter; and (iii) 6-[18F]fluoro-l-DOPA, to assess the activity of aromatic amino acid decarboxylase and storage of 6-[18F]- fluorodopamine in synaptic vesicles. The subjects with Parkinson's disease and the healthy controls underwent positron emission tomography scans at the initial visit and after 4 and 8 years of follow-up. Non-linear multivariate regression analyses with random effects were utilized to model the longitudinal changes in tracer values in the putamen standardized relative to normal controls. We found evidence for possible upregulation of dopamine synthesis and downregulation of dopamine transporter in the more severely affected putamen in the early stage of Parkinson's disease. The standardized 6-[18F]fluoro-l-DOPA and [11C]d-threo-methylphenidate values tended to approach [ 11C](±)dihydrotetrabenazine values in the putamen in later stages of disease (i.e. for [11C](±)dihydrotetrabenazine values

AB - Parkinson's disease is a relentlessly progressive neurodegenerative disease. Breakdown of compensatory mechanisms influencing putaminal dopamine processing could contribute to the progressive motor symptoms. We studied a cohort of 78 subjects (at baseline) with sporadic Parkinson's disease and 35 healthy controls with multi-tracer positron emission tomography scans to investigate the evolution of adaptive mechanisms influencing striatal dopamine processing in Parkinson's disease progression. Presynaptic dopaminergic integrity was assessed with three radioligands: (i) [11C](±) dihydrotetrabenazine, to estimate the density of vesicular monoamine transporter type 2; (ii) [11C]d-threo-methylphenidate, to label the dopamine transporter; and (iii) 6-[18F]fluoro-l-DOPA, to assess the activity of aromatic amino acid decarboxylase and storage of 6-[18F]- fluorodopamine in synaptic vesicles. The subjects with Parkinson's disease and the healthy controls underwent positron emission tomography scans at the initial visit and after 4 and 8 years of follow-up. Non-linear multivariate regression analyses with random effects were utilized to model the longitudinal changes in tracer values in the putamen standardized relative to normal controls. We found evidence for possible upregulation of dopamine synthesis and downregulation of dopamine transporter in the more severely affected putamen in the early stage of Parkinson's disease. The standardized 6-[18F]fluoro-l-DOPA and [11C]d-threo-methylphenidate values tended to approach [ 11C](±)dihydrotetrabenazine values in the putamen in later stages of disease (i.e. for [11C](±)dihydrotetrabenazine values

KW - compensatory changes

KW - motor dysfunction

KW - Parkinson's disease

KW - PET

KW - striatal dopamine processing

UR - http://www.scopus.com/inward/record.url?scp=81055144433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81055144433&partnerID=8YFLogxK

U2 - 10.1093/brain/awr233

DO - 10.1093/brain/awr233

M3 - Article

C2 - 22075521

AN - SCOPUS:81055144433

VL - 134

SP - 3290

EP - 3298

JO - Brain

JF - Brain

SN - 0006-8950

IS - 11

ER -